摘要
The research article by Li et al.demonstrated the clinical benefits of hepatic arterial infusion chemotherapy(HAIC)(also known as transarterial infusion chemotherapy)with FOLFOX compared with transarterial chemoembolization(TACE)and sorafenib in advanced hepatocellular carcinoma(HCC)patients(1).HAIC was still selected as a common treatment option for advanced HCC mostly in Asian countries even when multi-kinase inhibitors were established as the standard treatment.It is believed that experts in Asia fully understand HAIC’s clinical benefit for advanced HCC due to HAIC was a traditional transarterial treatment method which had evolved in Asia and performed before multi-kinase inhibitor development.The biggest reason HAIC had not become the global standard,even with the evidence of high-level efficacy,was the lack of well-designed clinical studies.
作者简介
Correspondence to:Sadahisa Ogasawara,MD,PhD.Department of Gastroenterology,Graduate School of Medicine,Chiba University,1-8-1 Inohana,Chuo-ku,Chiba,Japan.Email:ogasawaras@chiba-u.jp.ORCID:0000-0002-6540-9064.
